In conclusion, our findings implicate HSC activation in the pathophysiology of a relevant animal model of human NASH and strongly support roles for ETS1 and RUNX1 TFs as drivers of HSC activation and plasticity. This evidence concerns the gene RUNX1 and metabolic dysfunction-associated steatohepatitis.